Utah Medical Products Inc (UTMD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UTMD SEC filings page.
Utah Medical Products Inc (UTMD) reported $36.1M in revenue over the twelve months to Jun 30, 2026, down 7.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains highly cash-generative and nearly debt-free, but shrinking revenue has steadily compressed margins and returns since FY2022.
Revenue fell from$50.2M in FY2023 to$38.5M in FY2025, while operating cash flow remained about38.1% of FY2025 revenue; cash conversion stayed strong even as scale contracted. Free cash flow was$14.3M against operating cash flow of$14.7M in FY2025, so reinvestment consumed little operating cash—the main deterioration is profitability, not capital intensity.
Gross margin declined from
FY2025 liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Utah Medical Products Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Utah Medical Products Inc has an operating margin of 29.6%, meaning the company retains $30 of operating profit per $100 of revenue. This strong profitability earns a score of 94/100, reflecting efficient cost management and pricing power. This is down from 33.2% the prior year.
Utah Medical Products Inc's revenue declined 5.8% year-over-year, from $40.9M to $38.5M. This contraction results in a growth score of 8/100.
Utah Medical Products Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 37.62, Utah Medical Products Inc holds $37.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Utah Medical Products Inc converts 37.2% of revenue into free cash flow ($14.3M). This strong cash generation earns a score of 97/100.
Utah Medical Products Inc earns a strong 9.5% return on equity (ROE), meaning it generates $9 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 72/100. This is down from 11.8% the prior year.
Utah Medical Products Inc scores 46.52, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($237.4M) relative to total liabilities ($3.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Utah Medical Products Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Utah Medical Products Inc generates $1.30 in operating cash flow ($14.7M OCF vs $11.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Utah Medical Products Inc generated $8.5M in revenue in Q2 2026. This represents a decrease of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.
Utah Medical Products Inc's EBITDA was $2.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.0% from the same quarter a year earlier. Against the prior quarter it is down 11.2%.
Utah Medical Products Inc reported $2.7M in net income in Q2 2026. This represents a decrease of 11.9% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.
Utah Medical Products Inc earned $0.84 per diluted share (EPS) in Q2 2026. This represents a decrease of 10.6% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.
Cash & Balance Sheet
Utah Medical Products Inc generated $1.2M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 55.7% from the same quarter a year earlier. Against the prior quarter it is down 58.1%.
Utah Medical Products Inc held $87.5M in cash against $195K in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Utah Medical Products Inc's gross margin was 55.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.8 percentage points.
Utah Medical Products Inc's operating margin was 31.1% in Q2 2026, reflecting core business profitability. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
Utah Medical Products Inc's net profit margin was 31.5% in Q2 2026, showing the share of revenue converted to profit. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.6 percentage points.
Utah Medical Products Inc's ROE was 2.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Capital Allocation
Utah Medical Products Inc invested $154K in research and development in Q2 2026. This represents an increase of 14.1% from the same quarter a year earlier. It is unchanged from the prior quarter.
Utah Medical Products Inc spent $78K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 97.8% from the same quarter a year earlier. Against the prior quarter it is down 39.1%.
Utah Medical Products Inc invested $134K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 162.7% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.
UTMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M-14.3% | $8.7M-10.2% | $9.0M-1.2% | $9.8M-1.9% | $10.0M-4.3% | $9.7M-14.4% | $9.2M-25.8% | $10.0M-20.0% |
| Cost of Revenue | $3.8M-13.5% | $3.4M-17.5% | N/A | $4.2M+0.1% | $4.4M+5.1% | $4.2M-8.8% | N/A | $4.2M-18.3% |
| Gross Profit | $4.8M-15.0% | $5.3M-4.6% | $5.3M-1.1% | $5.6M-3.4% | $5.6M-10.5% | $5.5M-18.1% | $5.3M-25.0% | $5.8M-21.2% |
| R&D Expenses | $154K+14.1% | $154K0.0% | N/A | $167K-2.9% | $135K-47.1% | $154K-42.1% | N/A | $172K+24.6% |
| SG&A Expenses | $2.0M-13.6% | $2.6M+14.9% | N/A | $2.8M+23.6% | $2.3M-11.6% | $2.2M-14.7% | N/A | $2.3M-29.7% |
| Operating Income | $2.6M-17.1% | $2.6M-18.6% | N/A | $2.6M-21.9% | $3.2M-7.0% | $3.2M-18.8% | N/A | $3.3M-15.8% |
| EBITDA | $2.9M-27.0% | $3.2M-16.2% | N/A | $3.4M-17.3% | $3.9M-4.3% | $3.9M-15.2% | N/A | $4.1M-29.1% |
| Income Tax | $600K-23.9% | $578K-29.3% | N/A | $678K+10.1% | $788K+4.0% | $817K-3.0% | N/A | $616K-27.2% |
| Net Income | $2.7M-11.9% | $2.6M-14.4% | $2.6M-11.6% | $2.6M-26.2% | $3.0M-11.7% | $3.0M-23.1% | $2.9M-32.3% | $3.6M-9.5% |
| EPS (Basic) | $0.84-10.6% | $0.82-10.9% | $0.80-7.0% | $0.82-19.6% | $0.94-4.1% | $0.92-15.6% | $0.86-27.1% | $1.02-5.6% |
| EPS (Diluted) | $0.84-10.6% | $0.82-10.9% | $0.80-7.0% | $0.82-20.4% | $0.94-4.1% | $0.92-15.6% | $0.86-27.1% | $1.03-4.6% |
| Diluted Shares (Avg) | 3M-1.9% | 3M-3.8% | N/A | 3M-7.8% | 3M-8.1% | 3M-8.5% | N/A | 3M-4.4% |
Not reported in any period shown, so not listed: Interest Expense.
UTMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $124.6M+3.1% | $124.4M+1.5% | $122.5M0.0% | $122.0M-6.0% | $120.8M-7.1% | $122.5M-9.5% | $122.5M-9.5% | $129.7M-1.2% |
| Current Assets | $100.6M+6.6% | $100.4M+4.1% | $97.7M+1.5% | $96.5M-5.0% | $94.4M-7.8% | $96.4M-10.0% | $96.3M-9.4% | $101.7M-0.2% |
| Cash & Equivalents | $87.5M+6.5% | $87.4M+4.9% | $85.8M+3.4% | $84.3M-4.7% | $82.2M-7.9% | $83.3M-11.2% | $83.0M-10.7% | $88.5M+0.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $9.0M+9.4% | $8.7M+0.9% | $7.9M-10.0% | $8.1M-10.9% | $8.2M-9.1% | $8.6M-6.4% | $8.8M-8.0% | $9.1M-6.2% |
| Accounts Receivable | $3.6M-1.8% | $3.6M-7.8% | $3.5M-14.0% | $3.7M+0.1% | $3.6M-1.0% | $3.9M+9.8% | $4.1M+20.7% | $3.7M+6.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $14.0M-1.7% | $13.9M+1.1% | $14.1M+3.5% | $14.1M+0.2% | $14.2M+4.1% | $13.8M+1.0% | $13.6M-0.8% | $14.0M+4.5% |
| Total Liabilities | $2.5M-22.3% | $4.0M-26.7% | $3.3M-35.9% | $3.7M-32.3% | $3.3M-45.3% | $5.5M-28.9% | $5.1M-28.5% | $5.5M-27.1% |
| Current Liabilities | $2.1M-8.2% | $3.5M-18.9% | $2.6M-30.8% | $3.0M-12.3% | $2.3M-42.8% | $4.3M-21.0% | $3.8M-20.2% | $3.4M-17.8% |
| Non-Current Liabilities | $469K-53.8% | $504K-56.1% | $676K-50.1% | $712K-65.5% | $1.0M-50.3% | $1.1M-48.4% | $1.4M-44.4% | $2.1M-38.7% |
| Long-Term Debt | $195K | $210K-21.9% | $225K-20.2% | N/A | N/A | $269K | $282K-4.4% | N/A |
| Total Equity | $122.0M+3.8% | $120.4M+2.8% | $119.3M+1.6% | $118.3M-4.8% | $117.5M-5.3% | $117.0M-8.4% | $117.4M-8.5% | $124.2M+0.4% |
| Retained Earnings | $132.0M+4.0% | $130.3M+1.6% | $128.7M-0.5% | $128.0M-4.5% | $126.9M-6.3% | $128.2M-7.8% | $129.3M-6.5% | $134.1M-0.8% |
UTMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.4M-51.9% | $3.1M-30.4% | $3.5M+18.4% | $3.9M+0.6% | $2.9M+4.0% | $4.5M-15.4% | $2.9M-44.9% | $3.9M-24.7% |
| Depreciation & Amortization | $226K-69.6% | $673K-5.1% | $745K+3.9% | $754K+3.6% | $744K+9.3% | $709K+6.0% | $717K-30.1% | $728K-58.9% |
| Stock-Based Compensation | N/A | $120K+46.3% | N/A | N/A | N/A | $82K+3.8% | N/A | $53K0.0% |
| Capital Expenditures | $134K+162.7% | $130K-29.3% | $109K+1111.1% | $27K-69.7% | $51K-53.6% | $184K+736.4% | $9K-90.0% | $89K-52.2% |
| Free Cash Flow | $1.2M-55.7% | $3.0M-30.4% | $3.4M+15.0% | $3.9M+2.2% | $2.8M+6.4% | $4.3M-18.5% | $2.9M-44.1% | $3.8M-23.7% |
| Investing Cash Flow | -$134K-162.7% | -$130K+29.3% | -$109K-1111.1% | -$27K+69.7% | -$51K+55.7% | -$184K-3780.0% | -$9K+90.0% | -$89K+52.2% |
| Financing Cash Flow | -$1.1M+76.3% | -$1.1M+73.6% | -$2.0M+74.6% | -$1.6M+66.6% | -$4.5M+37.6% | -$4.2M-6.4% | -$7.7M-623.3% | -$4.9M-375.2% |
| Dividends Paid | $987K-1.4% | $989K-2.8% | $977K-5.9% | $988K-6.1% | $1.0M-7.4% | $1.0M-6.6% | $1.0M-3.1% | $1.1M-1.8% |
| Share Buybacks | $78K-97.8% | $128K-96.0% | $994K-85.2% | $653K-83.1% | $3.5M-45.5% | $3.2M+7.7% | $6.7M | $3.9M |
UTMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.8%-0.4pp | 60.6%+3.5pp | 58.2%+0.1pp | 57.1%-0.9pp | 56.2%-3.9pp | 57.0%-2.6pp | 58.1%+0.6pp | 58.0%-0.9pp |
| Operating Margin | 31.1%-1.1pp | 29.4%-3.1pp | N/A | 26.6%-6.8pp | 32.1%-1.0pp | 32.5%-1.8pp | N/A | 33.4%+1.7pp |
| Net Margin | 31.5%+0.9pp | 29.9%-1.5pp | 28.4%-3.3pp | 26.8%-8.8pp | 30.6%-2.6pp | 31.3%-3.6pp | 31.7%-3.1pp | 35.6%+4.1pp |
| Return on Equity | 2.2%-0.4pp | 2.2%-0.4pp | 2.1%-0.3pp | 2.2%-0.6pp | 2.6%-0.2pp | 2.6%-0.5pp | 2.5%-0.9pp | 2.9%-0.3pp |
| Return on Assets | 2.2%-0.4pp | 2.1%-0.4pp | 2.1%-0.3pp | 2.2%-0.6pp | 2.5%-0.1pp | 2.5%-0.4pp | 2.4%-0.8pp | 2.8%-0.2pp |
| Current Ratio | 48.62+6.7x | 28.64+6.3x | 37.62+12.0x | 32.06+2.5x | 41.87+15.9x | 22.29+2.7x | 25.64+3.1x | 29.59+5.2x |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.030.0x | 0.030.0x | 0.00-0.1x | 0.000.0x | 0.040.0x |
| Asset Turnover | 0.070.0x | 0.070.0x | 0.070.0x | 0.080.0x | 0.080.0x | 0.080.0x | 0.070.0x | 0.080.0x |
| FCF Margin | 14.6%-13.7pp | 34.2%-9.9pp | 37.2%+5.3pp | 39.3%+1.6pp | 28.3%+2.8pp | 44.1%-2.2pp | 32.0%-10.5pp | 37.6%-1.8pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Utah Medical Products Inc UTMD | FY2025 | $38.5M | $11.3M | 29.3% | $237.4M | 78/100 |
| InfuSystem Holdings, Inc. INFU | FY2025 | $143.4M | $6.6M | 4.6% | $268.7M | 59/100 |
| KORU Medical Systems, Inc. KRMD | FY2025 | $41.1M | -$2.6M | -6.4% | $138.5M | 66/100 |
| OraSure Technologies Inc OSUR | FY2025 | $115.0M | -$68.7M | -59.8% | $262.8M | 48/100 |
| Sharps Technology Inc. STSS | FY2025 | $204K | -$282.5M | N/A | $77.9M | — |
Where Utah Medical Products Inc Ranks
Frequently Asked Questions
What is Utah Medical Products Inc's annual revenue?
Utah Medical Products Inc (UTMD) reported $38.5M in total revenue for fiscal year 2025. This represents a -5.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Utah Medical Products Inc's revenue growing?
Utah Medical Products Inc (UTMD) revenue declined by 5.8% year-over-year, from $40.9M to $38.5M in fiscal year 2025.
Is Utah Medical Products Inc profitable?
Yes, Utah Medical Products Inc (UTMD) reported a net income of $11.3M in fiscal year 2025, with a net profit margin of 29.3%.
What is Utah Medical Products Inc's EBITDA?
Utah Medical Products Inc (UTMD) had EBITDA of $14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Utah Medical Products Inc have?
As of fiscal year 2025, Utah Medical Products Inc (UTMD) had $85.8M in cash and equivalents against $225K in long-term debt.
What is Utah Medical Products Inc's gross margin?
Utah Medical Products Inc (UTMD) had a gross margin of 57.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Utah Medical Products Inc's operating margin?
Utah Medical Products Inc (UTMD) had an operating margin of 29.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Utah Medical Products Inc's net profit margin?
Utah Medical Products Inc (UTMD) had a net profit margin of 29.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Utah Medical Products Inc's return on equity (ROE)?
Utah Medical Products Inc (UTMD) has a return on equity of 9.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Utah Medical Products Inc's free cash flow?
Utah Medical Products Inc (UTMD) generated $14.3M in free cash flow during fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Utah Medical Products Inc's operating cash flow?
Utah Medical Products Inc (UTMD) generated $14.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Utah Medical Products Inc's total assets?
Utah Medical Products Inc (UTMD) had $122.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Utah Medical Products Inc's capital expenditures?
Utah Medical Products Inc (UTMD) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Utah Medical Products Inc spend on research and development?
Utah Medical Products Inc (UTMD) invested $668K in research and development during fiscal year 2025.
What is Utah Medical Products Inc's current ratio?
Utah Medical Products Inc (UTMD) had a current ratio of 37.62 as of fiscal year 2025, which is generally considered healthy.
What is Utah Medical Products Inc's debt-to-equity ratio?
Utah Medical Products Inc (UTMD) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Utah Medical Products Inc's return on assets (ROA)?
Utah Medical Products Inc (UTMD) had a return on assets of 9.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Utah Medical Products Inc's P/E ratio?
Utah Medical Products Inc (UTMD) trades at 22.6x earnings, its market capitalization divided by net income of $10.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $237.4M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Utah Medical Products Inc's price-to-sales ratio?
Utah Medical Products Inc (UTMD) trades at 6.6x sales, its market capitalization divided by revenue of $36.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $237.4M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Utah Medical Products Inc's Altman Z-Score?
Utah Medical Products Inc (UTMD) has an Altman Z-Score of 46.52, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Utah Medical Products Inc's Piotroski F-Score?
Utah Medical Products Inc (UTMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Utah Medical Products Inc's earnings high quality?
Utah Medical Products Inc (UTMD) has an earnings quality ratio of 1.30x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Utah Medical Products Inc?
Utah Medical Products Inc (UTMD) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.